Company Product Description Indication Status
Oncoimmune Inc., of Rockville, Md. ONC-392 Next-generation anti-CTLA4 antibody Advanced solid tumors FDA cleared IND for phase Ia/IIb study to test drug as single agent in advanced solid tumors and in combination with anti-PD-(L)1 standard of care in non-small-cell lung cancer; study expected to start in early 2020
Urovant Sciences Ltd., of Irvine, Calif., and Basel, Switzerland Vibegron Once-daily beta-3 adrenergic agonist Overactive bladder Submitted NDA to FDA seeking approval to treat patients with symptoms of urge urinary incontinence, urgency and urinary frequency

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments